Sacubitril/Valsartanstive Heart Failure: Cardiogenic Shock.

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Sacubitril/valsartan represents a new class of heart failure medication, targeting both the angiotensin receptor and neprilysin.
• It is indicated for patients with symptomatic chronic heart failure with reduced ejection fraction.

Observation:

• A patient with New York Heart Association (NYHA) class IV systolic heart failure, refractory to standard therapies, was initiated on sacubitril/valsartan.
• The patient subsequently developed cardiogenic shock after starting the medication.

Findings:

• The introduction of sacubitril/valsartan in a patient with advanced, refractory heart failure led to a severe adverse event (cardiogenic shock).
• This suggests a potential risk associated with this medication in the critically ill heart failure population.

Implications:

• Reevaluation of sacubitril/valsartan's safety profile and risk-benefit ratio in NYHA class IV heart failure patients is warranted.
• Further research is needed to identify patient subgroups who may be at higher risk for adverse events.